Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

1.145 +0.005 (+0.44%)
Streaming Delayed Price Updated: 3:41 PM EDT, Mar 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces $150 Million Private Placement
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
RAPT Therapeutics Reports First Quarter 2024 Financial Results
Company maintains solid cash position of $141.6 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Company maintains solid cash position of $158.9 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
Company maintains strong cash position of $184.8 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
Company maintains strong cash position of $205 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports First Quarter 2023 Financial Results
Company maintains strong cash position of $231.6 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.